Abrdn Life Sciences Investors (HQL) Stock Price & Analysis
Abrdn Life Sciences Investors (HQL) closed at USD 17.73 on Friday, October 23, 2026, down 1.23% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 17.95; the Oct 23, 2026 session ranged USD 17.51–17.87 on volume of 60,789 shares. Market capitalization is —, with a 52-week range of USD 15.66–22.67 (NYQ). Source: Nexqual, retrieved October 24, 2026 at 09:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HQL.md
Key facts (HQL)
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $10K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y +19.2% vs S&P 500 +13.4%; 5Y +45.6% vs S&P 500 +76.9%.
Insider purchases (SEC Form 4, open-market, last ~7 months) (HQL)
1 purchase, $10K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-16 | Mahai Chris Lavictoire | Director | 527 | $10K | 19.92 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (HQL)
Consensus None.
Total return (dividends reinvested) (HQL)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +19.2% | +45.6% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +19.3% | +7.8% |
| Volatility (annualized) | 23.9% | 23.1% |
| Max drawdown | -23.9% (Aug 2026→Oct 2026) | -36.1% (Oct 2021→Oct 2023) |
Key Statistics (as of October 24, 2026 at 09:20 UTC)
| Price | USD 17.73 |
|---|---|
| Change | ▼ 1.23% (down) |
| Previous Close | USD 17.95 |
| Open | USD 17.99 |
| Day Range | USD 17.51 – 17.87 |
| 52-Week Range | USD 15.66 – 22.67 |
| Volume | 60,789 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (HQL)
Nexqual's technical model rates HQL "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 09:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.88 (neutral) |
| vs SMA50 | Below (USD 19.46) |
| MACD | -0.47 (negative) |
Analyst Ratings (HQL)
Wall Street analysts rate HQL "None", per Nexqual as of October 24, 2026 at 09:20 UTC.
| Consensus Rating | None |
|---|
Earnings (HQL)
Source: Nexqual, October 24, 2026 at 09:20 UTC.
Financials & Fundamentals (HQL)
| Total Revenue | $1.11M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -60.80% |
| Gross Margin | +100.00% |
| Operating Margin | -516.53% |
| Profit Margin | +17856.98% |
| ROE | +41.42% |
| Current Ratio | 1.61 |
| Total Cash | $851,602 |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 09:20 UTC.
Financial Health Score (HQL)
Nexqual rates Abrdn Life Sciences Investors's overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 09:20 UTC.
| Growth | Critical — Revenue -61% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $852K cash, no debt |
| Cash Flow | Solid — Operating cash flow $40M (TTM) |
| Efficiency | Strong — ROE 41%, ROA -0.6% |
Ownership (HQL)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +38.28% |
Source: Nexqual, October 24, 2026 at 09:20 UTC.
Leadership (HQL)
Abrdn Life Sciences Investors is led by Daniel R. Omstead M.S, Principal Executive Officer, President and Trustee, per Nexqual as of October 24, 2026 at 09:20 UTC.
| Principal Executive Officer, President and Trustee | Daniel R. Omstead M.S |
|---|
Major Backers & Investors (HQL)
Notable institutional backers of Abrdn Life Sciences Investors include Morgan Stanley, Penserra Capital Management LLC, Amplify ETF Trust-Amplify CEF High Income ETF, according to Nexqual as of October 24, 2026 at 09:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 5.83% |
| Penserra Capital Management LLC | 2.76% |
| Amplify ETF Trust-Amplify CEF High Income ETF | 2.75% |
| Raymond James Financial, Inc. | 2.27% |
| LPL Financial LLC | 1.69% |
| Allspring Global Investments Holdings, LLC | 1.5% |
| Needham Investment Management, L.L.C. | 1.46% |
| Flagship Harbor Advisors, LLC | 1.32% |
Source: Nexqual, October 24, 2026 at 09:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLK | BlackRock, Inc. | USD 1,118.25 | ▼ 1.67% |
| BX | Blackstone Inc. | USD 117.97 | ▼ 0.66% |
| BN | Brookfield Corporation | USD 37.97 | ▼ 0.81% |
| KKR | KKR & Co. Inc. | USD 91.34 | ▼ 1.88% |
| BAM | Brookfield Asset Management Inc | USD 47.03 | ▼ 1.28% |
| APO | Apollo Global Management, Inc. | USD 112.83 | ▼ 1.74% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 09:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt